In an effort to find new treatments for castrate-resistant prostate cancer, a TTUHSC research team led by Srinivas Nandana, ...

The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...

The FDA has expanded the approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and can delay chemotherapy.

First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone ...

Novartis (NVS) announced that the Food and Drug Administration approved Pluvicto for patients with prostate-specific membrane antigen-positive ...

The FDA approved a radioligand therapy for earlier use prior to chemotherapy in patients with prostate-specific membrane ...

Basel: Novartis has announced that the US Food and Drug Administration (FDA) has approved Pluvicto (lutetium Lu 177 ...

Novartis radioligand therapy, Pluvicto gets US FDA approval for earlier use before chemotherapy in PSMA-positive mCRPC: Basel Monday, March 31, 2025, 13:00 Hrs [IST] Novartis anno ...

"We are currently assessing exposure of short term (several weeks or less) androgens on reproductive parameters of female ...

FDA expands Pluvicto indication to adults with PSMA+ metastatic castration-resistant prostate cancer previously treated with ...